Xylesthesin A Injection

Adult administration

The injection rate should not exceed 0.5 mL every 15 seconds. Nerve block and infiltration anesthesia: Generally, 1 to 4 mL (20 to 80 mg of lidocaine hydrochloride) of this drug is sufficient. Do not exceed 6 mL (120 mg of lidocaine hydrochloride) within 2 hours and 10 mL (200 mg of lidocaine hydrochloride) within 24 hours.

Child administration

Generally, 20 to 30 mg of lidocaine hydrochloride is used, typically calculated as body weight (kg) x 1.33. The recommended dosage and injection volume based on weight are as follows: - 20-30 kg

This drug is an amide-type local anesthetic and should not be used in certain patients. First, individuals allergic to this drug or other amide-type local anesthetics should not be administered this medication. Also, patients with hypersensitivity to vasoconstrictors should avoid using this drug. Those with hypertension, arteriosclerosis, heart failure, hyperthyroidism, diabetes, or vascular diseases should consult a physician before using this medication. There are particularly cautious patients when using this drug. Patients using halothane or other halogen-containing inhalation anesthetics, or those taking tricyclic antidepressants or MAO inhibitors should be administered with caution. Older adults or patients with cardiac conduction disorders may also show worsening symptoms, so care should be taken. Patients with severe hepatic or renal dysfunction may easily exhibit signs of drug toxicity, requiring caution. Furthermore, pregnant women or those who may become pregnant should only use this medication if the benefits outweigh the risks. This drug contains sodium metabisulfite, which can cause severe allergic reactions or asthma attacks in some patients. Such reactions may occur more frequently in asthma patients, so caution is warranted. When using this drug, there is a risk of shock or acute toxicity symptoms, thus the patient's condition should be closely monitored; if any unusual symptoms occur, administration should be stopped immediately, and appropriate measures taken. Severe adverse reactions may include hypotension, abnormal pulse, respiratory depression, and malignant hyperthermia, which may occur rarely. In such cases, drug administration should be stopped immediately, and professional treatment is required. Central nervous system adverse symptoms may include tremors, seizures, drowsiness, anxiety, dizziness, and nausea; careful observation is necessary. This drug can interact with other medications, necessitating caution when used with halothane, tricyclic antidepressants, MAO inhibitors, beta-blockers, alpha-blockers, psychiatric medications, and vasoconstrictors. Women who are pregnant or breastfeeding should exercise caution regarding the administration of this drug, considering its effects on the baby during breastfeeding. Older adults may be more sensitive to the epinephrine in this drug, so administration should be done with careful monitoring of their condition. In case of overdose, there may be severe symptoms affecting the central nervous and cardiovascular systems; if symptoms appear, immediate notification to medical personnel is required, along with appropriate emergency treatment. Finally, this drug is strictly for dental use only and should not be used for other purposes.

Serious side effects

• Shock
• hypotension
• facial pallor
• abnormal pulse
• respiratory depression
• malignant hyperthermia
• tachycardia
• arrhythmia
• blood pressure fluctuations
• rapid temperature increase

Mild side effects

• Drowsiness
• anxiety
• excitement
• numbness
• dizziness
• nausea
• vomiting
• hives
• swelling

This drug is sensitive to light and should be stored in an opaque container. Additionally, it is important to store it at a cool temperature below 25 degrees Celsius to maintain its effectiveness.

Appearance

A colorless cartridge filled with a clear, transparent, colorless liquid

Package unit

1.7 mL/cartridge x 50